SCHEMBL10185175

SCHEMBL10185175

CCCc1ccc(C(=O)NCCNC(=O)c2ccc(O[C@H]3CC[C@@H](C(=O)O)CC3)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.50
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
OPRM1 P35372 2/20 0.49
OPRD1 P41143 2/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
NPC1 O15118 4/20 0.49
MAPT P10636 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
DGAT1 O75907 7/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
SLC5A7 Q9GZV3 1/20 0.46
HRH3 Q9Y5N1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10185149 0.91 DGAT1 (0.50) RAB9AMEN1KMT2AOPRM1OPRD1
SCHEMBL10184403 0.89 DGAT1 (0.54) MEN1KMT2AOPRM1OPRD1ALDH1A1
SCHEMBL10185050 0.89 HPGD (0.49) RAB9AMEN1KMT2AOPRM1OPRD1
SCHEMBL10184328 0.87 DGAT1 (0.51) RAB9AMEN1KMT2AOPRM1OPRD1
SCHEMBL10185016 0.87 RAB9A (0.59) RAB9AMEN1KMT2AALDH1A1NPC1
SCHEMBL10185018 0.87 RAB9A (0.59) RAB9AMEN1KMT2AALDH1A1NPC1
SCHEMBL10185119 0.86 NPC1 (0.56) RAB9AMEN1KMT2AALDH1A1NPC1
SCHEMBL10186427 0.86 DGAT1 (0.48) MEN1KMT2AOPRM1OPRD1ALDH1A1
SCHEMBL10185047 0.86 NPC1 (0.55) RAB9AOPRM1OPRD1ALDH1A1LMNA
SCHEMBL10185044 0.86 LMNA (0.54) LMNANPC1DGAT1L3MBTL1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed
WO-2010122968-A1 DIACYLETHYLENEDIAMINE COMPOUND アステラス製薬株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND DGAT1, DGAT2, DIMT1 RAB9A 1660/4885MEN1 2222/4885KMT2A 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.